Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Defining Which Remission Criterion At Month 6 Predicts Remission At Month 12 In A Real Life Clinical Practice, In A Cohort Of Ankylosing Spondylitis Patients Treated With Etanercept (Enbrel (Registered))

NCT02202850 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02202850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02202850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Defining Which Remission Criterion At Month 6 Predicts Remission At Month 12 In A Real Life Clinical Practice, In A Cohort Of Ankylosing Spondylitis Patients Treated With Etanercept (Enbrel (Registered))
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
August 12, 2014
Completion date
April 26, 2017
Enrollment
84 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis